[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fondation Hôpital Saint-Joseph\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":594},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,49,76,102,128,152,175,196,217,240,260,285,305,327,350,370,391,410,429,459,479,497,516,547,569],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100632382","phase-3-duration-of-dual-anti-platelet-therapy-in-chronic-limb-threatening-ischemia-after-distal-revascularization-100632382",false,"NCT07512960","Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization","Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization: a Randomized, Double-blind Trial PALADIN [PeripherAL Arterial DIsease Network] -DAPTCLTI","DAPTCLTI","Inclusion Criteria:\n\n* Age ≥18 years\n* Hospitalized patients with CLTI defined as Rutherford category 4 (ischemic rest pain) or 5 (minor tissue loss, non-healing ulcer, focal gangrene) evolving for \\> 2 weeks + one or more abnormal hemodynamic parameters: ankle-brachial index (ABI) \\\u003C0.4 (using higher of the dorsalis pedis and posterior tibial arteries), absolute highest ankle pressure \\\u003C50 mm Hg, absolute toe pressure \\\u003C30 mm Hg.\n* Successful endovascular revascularization involving below-the-knee arteries (angioplasty\u002Fstenting) alone or combining above- and below-the-knee revascularization within the last 7 days prior to randomization\n* Affiliation to a French Health Insurance system\n* Patient able to understand and sign a written informed consent form.\n* In women of childbearing potential: negative serum pregnancy test and use of adequate contraception.\n\n(According to CTFG guidelines, a woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.)\n\nExclusion Criteria:\n\n* PAD Rutherford category 0, 1, 2, 3 or 6 (Rutherford 6 defined as severe\n* ischemic ulcers or foot gangrene exceeding the digits)\n* Acute limb ischemia within one month prior to the qualifying revascularization\n* Platelet count \\\u003C 100x109\u002FL\n* Need for dual antiplatelet therapy for other reason than PAD\n* Need for concomitant treatment with anticoagulant (VKA or DOAC \\[except low dose rivaroxaban 2.5 mg x 2\\])\n* Known allergy or hypersensitivity to aspirin\u002Fclopidogrel\n* Exclusion criteria related to bleeding risks or systemic conditions:\n* Medical history or active clinically significant bleeding, lesions, or conditions within the last 6 months prior to inclusion, considered to be a significant risk for major bleeding (this may include current medically confirmed gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, current or recent brain or spinal injury, known esophageal varices, or major intraspinal or intracerebral vascular abnormalities;\n* Severe hepatic impairment or any known hepatic disease associated with coagulopathy or bleeding risk;\n* Any condition requiring dialysis or renal replacement therapy or a renal impairment at screening assessed with an estimated glomerular filtration rate \\\u003C15 mL\u002Fmin\u002F1.73 m2 (if a patient's eGFR is \\\u003C30 mL\u002Fmin\u002F1.73 m2 prior to the procedure, it must remain \\>15 mL\u002Fmin\u002F1.73 m2 72 hours after the procedure to enroll and randomize the patient);\n* Confirmed acute coronary syndrome (ACS) within 30 days prior to inclusion; Major trauma or accidents within 30 days prior to inclusion;\n* Any medically documented history of intracranial hemorrhage, stroke, or transient ischemic attack (TIA);\n* Known active malignancy (as determined through review of medical history), excluding local skin cancer (basal or squamous cell carcinoma);\n* Poorly controlled diabetes (at the discretion of the investigator);\n* Severe uncontrolled hypertension (at the discretion of investigator);\n* Other exclusion criteria :\n* Previous (within 30 days) or concomitant participation in another clinical interventional study (drug or device)\n* Close affiliation with the investigational site; e.g., a close relative of the investigator, dependent person (e.g., employee or student of the investigational site)\n* Expected impossible follow-up or poor compliance\n* Patient deprived of liberty\n* Patient under tutorship, curatorship, or legal protection\n* Documented pregnancy or lactation","ALL","18 Years","99 Years",{"count":22,"type":23},614,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","Chronic limb threatening ischemia (CLTI) is defined as ischemic foot pain at rest or non-healing foot wounds that is attributable to severe peripheral arterial disease (PAD).Revascularization is the cornerstone of therapy to relieve ischemic pain, prevent limb loss and preserve patient autonomy. Revascularization procedures often involve below-the-knee arterial disease in CLTI population. Dual antiplatelet therapy (DAPT, with aspirin, and clopidogrel) is recommended for at least 1-month after peripheral angioplasty. However, the exact duration of this DAPT remains controversial. Angioplasty of below-the-knee arteries is often followed by a longer period of DAPT, 3-months to one-year, due to a high risk of arterial thrombosis\u002Fstenosis.It will be the first trial on duration of DAPT in patients with below-the-knee angioplasty for CLTI, the end-stage of PAD",[29],"CLTI Defined as Rutherford Category 4 or 5",[31,32,33,34,35],"Arterial angioplasty","Percutaneous transluminal angioplasty","Arterial thrombosis limb","Arterial thrombosis","Atherothrombosis","RECRUITING","2026-06-19",{"date":39,"type":40},"2026-06-24","ACTUAL",{"date":42,"type":40},"2026-06-12",{"date":44,"type":23},"2030-11-30",{"name":46,"class":47},"Fondation Hôpital Saint-Joseph","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":48},"100638552","phase-2-effect-of-vasopressin-versus-norepinephrine-on-post-operative-mean-pulmonary-arterial-pressure-following-pulmonary-endarterectomy-surgery-100638552","NCT07614438","Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery,","Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery, a Randomized Open Label Trial","VANOPE","Inclusion Criteria:\n\n* Age ≥18 years;\n* Patient scheduled for pulmonary endarterectomy surgery;\n* In women of childbearing potential: negative serum pregnancy test and use of adequate contraception;\n* Affiliation to the French social care service;\n* Patient able to understand and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Emergency surgery;\n* Mesenteric ischemia and\u002For acute coronary syndrome within the month preceding the intervention;\n* Patients with documented mesenteric artery stenosis;\n* Impossibility to insert the pulmonary artery catheter (anatomical or technical issue);\n* Preoperative administration of norepinephrine and\u002For inotropic drugs (dobutamine, isoproterenol, epinephrine) or patients assisted by veno-venous or veno-arterial ECMO before surgery;\n* Known allergy to the active substance vasopressin or to any of its excipients;\n* Concomitant coronary bypass procedure or other combined surgery (i.e. valve replacement);\n* mPAP\\\u003C25 mmHg on preoperative right heart catheterization;\n* Patient with preoperative natremia below 130 mol\u002FL;\n* Patient participating to another interventional clinical trial;\n* For females only: documented pregnancy or lactation;\n* Patient under tutorship, curatorship or legal protection;\n* Patient deprived of liberty.",{"count":58,"type":23},90,[60],"PHASE2","Chronic thromboembolic pulmonary hypertension (CTEPH), one of the leading causes of pulmonary hypertension (PH), is caused by the chronic obstruction of the pulmonary arteries following episode of pulmonary embolism. It is the only cause of PH which is accessible to a potential curative surgical treatment: the pulmonary endarterectomy (PEA). Because of their underlying disease (pulmonary hypertension and potential right heart dysfunction), anesthesia should be performed cautiously. Perioperative hemodynamic management often requires the administration of a vasopressor to maintain the arterial pressure above a specific threshold of 65 mmHg.\n\nLow dose of vasopressin increases systemic arterial pressure with minimal effects on the pulmonary circulation. This profile suggests that vasopressin may be an ideal agent for vasopressor support in the high-risk population of patients with pulmonary hypertension.\n\nTo date, there is no data on the use of vasopressin in patient undergoing PEA surgery. The interesting properties of vasopressin - specifically, its ability to increase systemic arterial resistance while having a low impact on pulmonary resistance and offering potential renal protective effects - are highly advantageous in the specific subset of patient scheduled for PEA.\n\nThe investigators aim to conduct a randomized single center open label study to compare the effect of vasopressin compared to norepinephrine on mean pulmonary artery pressure after PEA surgery.\n\nThe primary objective of this study is to determine whether the use of vasopressin compared to norepinephrine decrease the mean pulmonary artery pressure after PEA surgery.\n\nParticipation to the study involves follow up at day 30 following surgery.",[63,64,65,66],"Anesthesia","Pulmonary Hypertension","Chronic Pulmonary Thromboembolism","Vasopressor","NOT_YET_RECRUITING","2026-05-29",{"date":70,"type":40},"2026-06-02",{"date":72,"type":23},"2026-08-01",{"date":74,"type":23},"2028-09-01",{"name":46,"class":47},{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":24,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100632378","study-of-factors-influencing-the-dynamics-of-colonisation-and-decolonisation-of-the-digestive-tract-by-clostridioides-difficile-in-infants-100632378","NCT07512908","Study of Factors Influencing the Dynamics of Colonisation and Decolonisation of the Digestive Tract by Clostridioides Difficile in Infants","Study of Factors Influencing the Dynamicsof Colonisation and Decolonisation of the Digestive Tract by Clostridioides Difficile in Infants","BBDIFF","For mothers\n\n* Women aged 18 or over who are pregnant\n* Patients who have been informed and have consented to participate in the research\n* Patient affiliated with a health insurance plan (beneficiary or dependent), For minor patients (children)\n* unborn child\n* at least one parent of the child included is French-speaking\n* written consent from both parents for participation in the study criteria for non-inclusion parents under guardianship or trusteeship parents deprived of their liberty parents under judicial protection children born under X\u002For in foster care",true,{"count":86,"type":23},200,[88],"NA","Clostridioides difficile (formerly C. difficile) is a bacterium found in the form of spores (a resistant form) to which patients may be exposed in a hospital environment. Once ingested, the spore can germinate in the digestive tract in its vegetative form (active form of the bacterium) and then takes on the appearance of a Gram-positive bacillus that colonizes the digestive microbiota. This preliminary stage of digestive colonization by the bacterium is facilitated by certain factors, in particular exposure to antibiotics, which disrupt the composition of the digestive microbiota (dysbiosis) and thus facilitate the establishment of C. difficile following the removal of the barrier effect of the digestive microbiota. Certain strains (known as \"toxinogenic\") are then able to produce the main virulence factors (toxins A (TcdA) and B (TcdB)), thereby causing the main clinical signs of digestive infection, particularly in patients with risk factors for C. difficile infection (elderly people, progressive cancer, immunodepression, etc.).The treatment of CDI is mainly based on the oral administration of anti-Clostridioides difficile antibiotics such as Fidaxomicin (FDX) or Vancomycin (VAN) for a period of 10 days, according to the European recommendations of the ESCMID and the American recommendations of the IDSA. Despite effective treatment, CDI is characterized by a high recurrence rate of up to 25% of cases, with multiple recurrences that can be particularly debilitating for patients. The effect of disruption of the gut microbiota (dysbiosis) following exposure to antibiotics can be explained by several non-exclusive hypotheses, such as the disappearance of protective bacterial species in the gut microbiota or, conversely, the appearance of bacterial species that favor the colonization of C. difficile.\n\nHospitalization, and more generally healthcare, has often been identified as a risk factor for CDI.Indeed, C. difficile is found ubiquitously in the environment and contaminates food products. It is still difficult to assess the frequency of contamination through the ingestion of contaminated food and the potential colonization of the host.\n\nOnly the composition of the gut microbiota appears to be an interesting avenue to explore, especially since it changes significantly during the first year of life as important events occur, including dietary diversification with the introduction of the first solid foods.",[91],"Bacteria Infection Mechanism",[93],"characterize the kinetics of digestive colonization and decolonization (clearance) by C. difficile","2026-04-07",{"date":96,"type":40},"2026-04-13",{"date":98,"type":23},"2026-05-30",{"date":100,"type":23},"2029-12-31",{"name":46,"class":47},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":24,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":48},"100632372","evaluation-of-the-benefits-of-hypnosis-during-transoesophageal-echocardiography-100632372","NCT07512830","Evaluation of the Benefits of Hypnosis During Transoesophageal Echocardiography","HYPNOECHO","Inclusion Criteria:\n\nPatient aged ≥ 18 years old\n\n* Patient requiring a transoesophageal ultrasound scan under local anaesthetic.\n* Patient affiliated to a health insurance scheme\n* French-speaking patient\n* Patient who has given their free, informed and express verbal consent\n\nExclusion Criteria:\n\nPatient with a contraindication to transoesophageal ultrasound (significant radiation exposure to the chest, oesophageal pathology with risk of bleeding)\n\n* Patients with known schizophrenia or known psychiatric illness (documented in medical records)\n* Patients with known dementia or known cognitive impairment (documented in medical records)\n* Patients already included in an interventional research protocol\n* Patients under guardianship or curatorship\n* Patients deprived of their liberty\n* Patients under judicial protection\n* Pregnant or breastfeeding patients",{"count":110,"type":23},150,[88],"Transoesophageal echocardiography (TOE) is a routine cardiology examination that is performed in most cases under local anaesthesia and is recommended for many indications.The objective of our study will be to evaluate the expected beneficial effect of using conversational hypnosis and hypnosis during a transoesophageal ultrasound examination performed directly in the examination room by the cardiologist conducting the examination.",[114],"Cardio Vascular Disease",[116,117,118,119],"stroke","endocarditis","local anaesthetic","Conversational hypnosis","2026-04-03",{"date":122,"type":40},"2026-04-06",{"date":124,"type":40},"2026-02-18",{"date":126,"type":23},"2028-12-15",{"name":46,"class":47},{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":18,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":24,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":48},"100599601","obstructive-sleep-apnea-hypopnea-syndrome-osahs-and-transverse-orthodontic-deficiency-in-children-100599601","NCT07086612","Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) and Transverse Orthodontic Deficiency in Children","ASCOT","Inclusion Criteria:\n\n* Patient aged between 6 and 16 years\n* Patients with a transverse orthodontic deficiency (group \"CAS\")\n* Patients with another type of orthodontic deficiency (group \"CONTROL\") such as tooth rotation, crowding, mild Angle Class II or Class III dental occlusion\n* Patient who has given free, informed oral consent\n* Patient whose legal representatives have given their free written consent\n* Patient affiliated with a health insurance scheme\n\nExclusion Criteria:\n\n* Patients refusing to participate in the study\n* Patients whose legal representatives refuse to participate in the study","6 Years","16 Years",{"count":138,"type":23},102,[88],"OSAHS (Obstructive Sleep Apnea Hypopnea Syndrome) in children is a frequent respiratory disorder, whose prevalence is estimated at between 1.2 and 5.7%, and which, if left untreated, can cause severe medical complications. This prevalence tends to be underestimated. Diagnosis is made following a clinical examination noting the presence of characteristic clinical and polysomnographic criteria. Multidisciplinary management has been widely described in the literature, and various therapeutic options have been indicated. Rapid maxillary expansion has proved highly effective in the treatment of this condition. This syndrome is a real public health problem and must be diagnosed as early as possible. Through our research, we would like to study whether there is a causal link between an orthodontic problem of the transverse direction and the presence of SAHOS in children. In other words, we would like to assess whether children who clinically present an orthodontic deficiency of their transverse dimension are more likely to develop SAHOS than children without this deficit. If this proves to be true, then a new clinical sign could enable certain healthcare professionals to detect this syndrome early, and be able to refer patients to physicians as soon as possible.",[142,143],"Obstructive Sleep Apnea","Transverse Maxillary Deficiency","2026-03-27",{"date":146,"type":40},"2026-03-30",{"date":148,"type":40},"2025-11-06",{"date":150,"type":23},"2026-09-30",{"name":46,"class":47},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":24,"phases":160,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":48},"100617018","evaluation-of-the-effect-of-music-during-nursing-care-on-the-confort-of-patient-hospitalized-in-intensive-care-unit-during-the-acute-phase-of-a-stroke-100617018","NCT07313163","Evaluation of the Effect of Music During Nursing Care on the Confort of Patient Hospitalized in Intensive Care Unit During the Acute Phase of a Stroke","MELODHYA","Inclusion Criteria:\n\n* French-speaking patient\n* Aged 18 years or older\n* Diagnosed with a stroke\n* Hospitalized in a Neurovascular Intensive Care Unit (USINV)\n* Requiring a complete bed bath by a nurse or nursing assistant\n* Affiliated with a health insurance scheme\n* Having provided free, informed, and explicit consent\n\nExclusion Criteria:\n\n* Patient hospitalized for a reason other than stroke\n* Patient with comprehension disorders (aphasia with impaired comprehension, cognitive disorders predating the stroke, confusion, non-French-speaking)\n* Blind patient\n* Patient under guardianship or curatorship\n* Patient deprived of liberty or under legal protection (sauvegarde de justice)",{"count":138,"type":23},[88],"Nurses in Stroke Units and Neurovascular Intensive Care Units (USINV) provide care for patients who have experienced a stroke, a sudden and often devastating event that can result in motor, sensory, visual, cognitive, language, or swallowing impairments. Despite advances in stroke management, it remains the leading cause of acquired disability and the second leading cause of death in France, with 122,422 hospitalizations in 2022 and 773 at our institution in 2023. Acute stroke care guidelines recommend hospitalization in specialized neurovascular intensive care units (USINV), as this setting improves survival and recovery through specialized nursing care, close monitoring, and prevention of complications. However, the sudden onset of disability and the unfamiliar, often stressful hospital environment can lead to anxiety, fear, and a sense of helplessness among patients.\n\nProviding comfort is a key nursing objective in this context. Kolcaba defines comfort as the experience of having fundamental needs for relief, well-being, and transcendence met in physical, psycho-spiritual, environmental, and sociocultural dimensions. Hygiene care, in particular, can contribute to comfort by ensuring cleanliness, minimizing pain, and improving self-image. The use of music during care has been proposed as a means to enhance comfort by positively influencing both physical and psychological states, as well as the care environment. Music can stimulate the senses, redirect attention, evoke pleasant memories, reduce stress, and provide a sense of control and identity for patients.\n\nWhile music therapy-a specialized practice requiring trained professionals-has been studied in various fields, the use of music during routine care is distinct and has shown benefits in psychiatry, palliative care, and geriatrics, as well as during stressful procedures. In stroke rehabilitation, music has been explored for its effects on mood and recovery, but its use during the acute phase of stroke in USINV has not been systematically studied. An informal survey at our institution revealed that 78% of nurses and nursing assistants use music during care, particularly during hygiene procedures.\n\nOur hypothesis is that incorporating music into hygiene care can improve patient comfort by addressing physical, psychological, and environmental needs. To assess comfort in a population that may have communication difficulties, we developed a visual comfort scale (0-5) using artificial intelligence-generated facial expressions. This scale was tested on 30 USINV patients and found to be accessible and easy to use, except for those with cognitive impairments or language barriers, who will be excluded from further study.",[163],"Stroke",[116,165,166],"nursing care","music","2026-02-26",{"date":169,"type":40},"2026-02-27",{"date":171,"type":40},"2026-02-11",{"date":173,"type":23},"2027-07",{"name":46,"class":47},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":185,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":48},"100518415","clostridioides-difficile-infection-analyzing-clinic-evolution-and-bacterial-clearance-100518415","NCT06030245","Clostridioides Difficile Infection: Analyzing CLInic Evolution and Bacterial Clearance","Clostridioides Difficile Infection: Prospective Cohort Analyzing CLInic Evolution and Bacterial Clearance","DECLIC","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Patients hospitalized in a department of GH Paris Saint-Joseph with a microbiologically documented Clostridioides difficile infection or a microbiologically documented Clostridioides difficile recurrence.\n* Patient to be treated for Clostridioides difficile infection\n* French-speaking patient\n* Patients who do not object to their participation in the study\n\nExclusion Criteria:\n\n* Patients under guardianship or curatorship\n* Patient deprived of liberty\n* Patient under court protection\n* Pregnant or breast-feeding patient",{"count":184,"type":23},100,"OBSERVATIONAL","Clostridioides difficile (formerly Clostridium) is a bacterium found in the form of spores (resistance form) in the environment to which patients may be exposed. This bacterium used to belong to the Clostridium genus, but analysis of its 16S ribosomal RNA in 2016 led to its being distinguished from it. Once the spore has been ingested, it can germinate in vegetative form (the active form of the bacterium), taking on the appearance of a Gram-positive bacillus that will colonize the digestive microbiota. This preliminary stage of digestive colonization by the bacteria is facilitated by certain factors, notably nasogastric probing, antacids, etc. Antibiotics, for their part, disrupt the bacteria of the digestive microbiota (dysbiosis), thus facilitating the implantation of C. difficile. Certain strains (known as toxigenic) will produce the main virulence factors: toxins A (TcdA) and B (TcdB) ± a third toxin (binary toxin or CDT), and thus cause the main clinical signs of digestive infection, particularly in patients with risk factors for C. difficile infection (progressive cancer, immunodepression, etc.).\n\nClostridioides difficile infection (CDI) is characterized by variable clinical presentations, ranging from simple watery diarrhea without colitis, which often resolves spontaneously, to severe forms with complications such as pseudomembranous colitis, intestinal perforation or septic shock, which have a very poor prognosis.\n\nManagement of this type of CDI relies mainly on the oral administration of anti-clostridium difficile antibiotics such as fidaxomicin (FDX) or vancomycin (VAN) for 10 days, as recommended by the European ESCMID, British and American IDSA guidelines. Oral metronidazole is recommended only in the absence of availability of the first two molecules (community use). Despite this treatment, one of the main characteristics of CDI is a high recurrence rate, which can reach 25% of cases. With FDX, recurrence rates appear to be lower, especially as its administration regimen is optimized. Nevertheless, its high cost is a barrier to its wider use.\n\nIn view of the high cost to the community of treating recurrences, and the reduced quality of life of patients suffering from these recurrences, which are sometimes multiple and highly incapacitating, reducing the occurrence of recurrences is a major challenge. A better understanding of the factors leading to recurrence is therefore a prerequisite for optimizing CDI prevention and treatment strategies.\n\nThe study of colonic mucosal immunity (aimed at quantifying IgA in stools) could also contribute to a better understanding of patient progress.\n\nAll these issues surrounding CDI and its management justify the setting up of a prospective cohort for the longitudinal follow-up of infected patients, enabling us to study the digestive clearance of the bacteria according to various factors, notably the digestive microbiota and the mucosal immune response.",[188],"Clostridium Difficile Infections",{"date":190,"type":40},"2026-03-02",{"date":192,"type":40},"2023-09-18",{"date":194,"type":23},"2027-01-17",{"name":46,"class":47},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":24,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":216},"100491120","phase-3-glucocorticoids-versus-placebo-for-the-treatment-of-acute-exacerbation-of-idiopathic-pulmonary-fibrosis-100491120","NCT05674994","Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis","Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Randomized Controlled Trial","EXAFIP2","Inclusion Criteria:\n\n1. Patient is ≥ 18 years of age\n2. IPF or IPF (likely) diagnosis defined on 2018 international recommendations\n3. Definite or suspected Acute Exacerbation defined by the international working group criteria after exclusion of alternative diagnoses of acute worsening\n\n   \\*The criteria of IPF-AE are as follows:\n   * Previous or concurrent diagnosis of IPF (a)\n   * Acute worsening or development of dyspnea typically \\\u003C 1-month duration\n   * Computed tomography with new bilateral ground-glass opacity and\u002For consolidation superimposed on a background pattern consistent with usual interstitial pneumonia pattern (b)\n   * Deterioration not fully explained by cardiac failure or fluid overload Patients who fail to meet all 4 criteria due to missing computed tomography should be considered as having \"suspected Acute Exacerbation\".\n\n     1. If the diagnosis of IPF is not previously established, this criterion can be met by the presence of radiologic and\u002For histopathologic changes consistent with usual interstitial pneumonia pattern on the current evaluation.\n     2. If no previous computed tomography is available, the qualifier \"new\" can be dropped from the third criterion.\n4. For women of childbearing age: efficient contraception for the duration of the study\\*\n\n   \\*Effective contraception is defined as any contraceptive method that is used consistently and appropriately and has a low failure rate (i.e., less than 1% per year)\n5. Affiliation to the social security\n6. Patient able to understand and sign a written informed consent form or in case of incapacity of the patient to a relative whom understand and sign a written informed consent form\n\nExclusion Criteria:\n\n1. Identified etiology for acute worsening (i.e.: infectious disease)\n2. Known hypersensitivity to glucocorticoids or to any component of the study treatment\n3. Patient requiring mechanical ventilation or already on mechanical ventilation\n4. Active bacterial, viral, fungal or parasitic infection. On swab collected, only positive for SARS-CoV-2, Influenzae A, Influenzae B and Respiratory Syncytial Virus (RSV) result, are considered active viral infection. The others viruses (i.e. Rhinovirus, Adenovirus…) are not considered to be responsible of pneumonia.\n5. Active cancer\n6. Patient on a lung transplantation waiting list\n7. Treatment with glucocorticoids \\> 1 mg\u002Fkg\u002Fd from more than 7 days in the last 15 days\n8. Patient participating to another interventional clinical trial\n9. Documented pregnancy or lactation\n10. Patient under tutorship or curatorship\n11. Patient deprived of liberty\n12. Patient under court protection",{"count":205,"type":23},110,[26],"Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with a poor prognosis, with a 3-month mortality rate of over 50%. To date, no treatment has been proven to be effective in AI-FPI. The interest of glucocorticoids is controversial and needs to be confirmed. This confirmation is mandatory to validate the improvement of the prognosis of EA-IPF under this treatment but also to search for unsuspected deleterious effects as it has been shown with immunosuppressants in stable idiopathic pulmonary fibrosis.",[209],"Acute Exacerbation of Idiopathic Pulmonary Fibrosis",{"date":190,"type":40},{"date":212,"type":40},"2023-10-26",{"date":214,"type":23},"2026-12-31",{"name":46,"class":47},29,{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":224,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":185,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":48},"100627385","lived-experience-and-perceptions-of-menopause-among-patients-participating-in-the-multidisciplinary-care-pathways-at-paris-saint-joseph-hospital-100627385","NCT07447947","Lived Experience and Perceptions of Menopause Among Patients Participating in the Multidisciplinary Care Pathways at Paris Saint-Joseph Hospital","REVE","Inclusion Criteria:\n\n* Women\n* Between age 45 and age 60\n* French speaking\n* participating in the multidisciplinary program offered a the Paris Saint Joseph Hospital\n* Patient who does not object to the use of these data for research purposes\n\nExclusion Criteria:\n\n* Patient under guardianship or conservatorship\n* Patient deprived of liberty (incarcerated or institutionalized)\n* Patient under judicial protection","FEMALE","45 Years","60 Years",{"count":228,"type":23},24,"Menopause, often reduced to its biological aspects, is increasingly studied through medical, psychological, social, and cultural lenses. Women's experiences vary widely depending on context-country, era, and social status. Their perceptions are ambivalent: while some associate menopause with the end of fertility and burdensome physical symptoms (hot flashes, joint pain, sleep disorders, mood swings, brain fog, vaginal dryness, low libido, weight gain), others see it as a liberating phase, free from reproductive expectations. Surprisingly, 87% of women report a positive experience of menopause itself, though the transitional phase is less well-tolerated (78%).\n\nIn France, where women's life expectancy is 87, they spend a third of their lives post-menopause. Yet, menopause remains a taboo subject. While 87% of women aged 50-65 experience at least one symptom beyond the cessation of menstruation, 25% suffer severe symptoms. The silence around menopause is striking: 48% of women under 50 find it difficult to discuss, 39% of pre-menopausal women feel anxious, 46% have never discussed it with their partner, and only 61% have consulted a healthcare professional. This silence stems from outdated sexist views, societal valorization of youth, lack of intergenerational dialogue, and insufficient targeted health policies, leading to isolation and invisibility.\n\nMedical support often focuses on a biomedical model, particularly Hormone Replacement Therapy (HRT), which remains controversial since the 2002 WHI study. Only 2.5% of French women over 45 currently use HRT, and 45.4% view it negatively. However, women's experiences extend far beyond hormonal concerns.\n\nTo address these gaps, multidisciplinary programs-such as those at Paris Saint-Joseph Hospital and Toulouse University Hospital-offer group-based approaches, addressing physical, psychological, and relational dimensions. These programs provide a much-needed space for exchange, often absent in traditional care. Research on the benefits of collective discussion spaces (in-person or digital) in menopause care is limited, making it relevant to explore how these programs influence women's perceptions of menopause, their bodies, and their healthcare journey. While qualitative studies have examined individual experiences, few have focused on the dynamics of shared dialogue.",[231],"Menopause","2026-02-25",{"date":234,"type":40},"2026-03-04",{"date":236,"type":23},"2026-05",{"date":238,"type":23},"2027-03",{"name":46,"class":47},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":224,"minAge":19,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":185,"phases":4,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":257,"leadSponsor":259,"locationsCount":48},"100603275","prevalence-and-functional-impact-of-urinary-incontinence-in-women-with-chronic-obstructive-pulmonary-disease-undergoing-rehabilitation-a-cross-sectional-study-100603275","NCT07134400","Prevalence and Functional Impact of Urinary Incontinence in Women With Chronic Obstructive Pulmonary Disease Undergoing Rehabilitation: a Cross-sectional Study","PURGE","Inclusion Criteria:\n\n* Women aged 45 years or older\n* Patients diagnosed with GOLD stage II to IV Chronic Obstructive Pulmonary Disease (COPD)\n* Patients undergoing pulmonary rehabilitation for COPD in a specialized center\n* Patients able to complete the entire pad test\n* Patients with no more than 3 pregnancies in their lifetime \\[9\\]\n* Patients covered by a health insurance plan\n* French-speaking patients\n* Patients who have not objected to participating in this research\n\nExclusion Criteria:\n\n* Patients who have undergone surgery in the pelvic or thoracic region less than one year ago\n* Patients under guardianship or curatorship\n* Patients deprived of liberty\n* Patients under legal protection (safeguarding justice)\n* Pregnant or breastfeeding patients",{"count":184,"type":23},"Chronic Obstructive Pulmonary Disease (COPD) is a pathology characterized by progressive bronchial obstruction associated with an abnormal inflammatory response, leading to chronic cough, increased bronchial secretions, and irreversible destruction of alveolar walls according to the French-Language Pulmonology Society, in 2023, over 1.3 million patients were treated for this condition in France. The World Health Organization ranks COPD as the third leading cause of mortality worldwide. Historically, COPD predominantly affected men due to higher smoking rates. However, with the rise in smoking among women, recent studies have shown that the prevalence of COPD in women increased from 28 to41 perr 10,000 between 2006 and 2015. Moreover, the clinical presentation of the disease differs between genders. For equivalent smoking exposure, women appear to be more severely affected than men, experiencing greater dyspnea and a higher risk of exacerbations, leading to more frequent hospitalizations and a generally poorer quality of life.\n\nBeyond pulmonary impairment, another clinically significant but often underestimated symptom affecting quality of life is urinary incontinence. It appears more common in individuals with COPD, particularly due to chronic cough, repeated abdominal hyperpressure, and pelvic floor muscle imbalance. A few studies have investigated the prevalence of urinary incontinence in people with COPD. One study, involving 995 individuals with COPD, suggested that 34.9% experienced urinary leakage. However, this was a subjective measure based on self-reported data via a simple questionnaire in a case-control study.\n\nAnother Swedish study estimated the prevalence of urinary incontinence in individuals with COPD at 49.6% in women and 30.3% in men, indicating that women may be at higher risk of developing this symptom. Beyond these studies, the current scientific literature remains relatively limited on this topic, while the impact on patients' quality of life appears to be significant. Among the available studies, one of the most comprehensive was published in 2013 and relied solely on self-administered questionnaires distributed to a broad population (across all disease stages) outside the rehabilitation setting.\n\nThis overlapping symptomatology-combining COPD and urinary incontinence-profoundly affects patients' quality of life, physically, psychologically, as well as socially. The consequences include limited activities, social withdrawal, diminished self-esteem, and persistent discomfort in daily interactions. This situation can lead to social anxiety or fear of leakage, resulting in absenteeism or abandonment of pulmonary rehabilitation sessions, thereby compromising the effectiveness of treatment. Reduced participation in physical activity perpetuates a vicious cycle: muscle deconditioning, sarcopenia, or even malnutrition, which worsens dyspnea, loss of autonomy, and increases the risks of frailty, infections, and hospitalizations. The study by M. A. Ramon et al. (2018) illustrates this \"vicious cycle,\" where impaired respiratory and physical capacities are self-sustaining. Without specific screening or management strategies for urinary incontinence in this context, breaking this downward spiral and improving overall care trajectories becomes challenging.\n\nRaising awareness about the importance of screening for stress urinary incontinence in women with COPD-particularly during pulmonary rehabilitation sessions, where these symptoms are often overlooked due to lack of knowledge and available treatments-is crucial. Such screening would enhance our understanding of the link between chronic cough, stress urinary incontinence, and quality of life. Establishing a correlation between these factors would allow for tailored care pathways and referral of certain patients to targeted pelvic floor rehabilitation.\n\nA better understanding of this phenomenon is essential to improve functional assessment and propose adapted therapeutic approaches, which could be the subject of an interventional study in the future. This study thus represents an initial exploratory step aimed at better understanding the prevalence of urinary incontinence in women with COPD undergoing rehabilitation, as well as its impact on quality of life and cough function. It is a preliminary, observational study whose results will lay the foundation for future interventional research.",[250,251,252],"COPD (Chronic Obstructive Pulmonary Disease)","Urinary Incontinence (UI)","Pulmonary Rehabilitation","2026-01-30",{"date":255,"type":40},"2026-02-02",{"date":255,"type":23},{"date":258,"type":23},"2027-11",{"name":46,"class":47},{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":24,"phases":268,"briefSummary":269,"conditions":270,"keywords":273,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":48},"100619704","real-world-evidence-to-assess-the-value-of-a-digital-care-coordination-and-monitoring-program-for-supporting-caregivers-of-adults-discharged-from-the-emergency-department-100619704","NCT07348081","Real World Evidence to Assess the Value of a Digital Care Coordination and Monitoring Program for Supporting Caregivers of Adults Discharged From the Emergency Department.","RW-HOMECARE","Inclusion Criteria:\n\nFOR THE PATIENT\n\n* Person aged 18 or over, treated in the Emergency Department or Emergency Beds\n* Affiliated with Social Security\n* Having an adult non-professional relative helping them with one or more activities of daily living\n* Having a medical decision to return home within the next 72 hours\n* Who has given their free, informed, and express consent FOR THE CAREGIVER\n* Individuals aged 18 or older\n* Who are non-professional caregivers as defined in Article L. 113-1-3 of the Social Action and Families Code, living with or separately from the person being cared for (20)\n* Providing assistance to the patient with one or more activities of daily living, i.e., shopping, medical appointments, coordination of care, administrative tasks, and moral support\n* Access to a cell phone, computer, or tablet with an internet connection\n* Having given their free, informed, and express consent\n\nExclusion Criteria:\n\nFOR THE PATIENT\n\n* Non-French speakers\n* People living in a medical institution or scheduled for institutionalization within the next 3 months\n* People receiving home hospitalization (HAD) or palliative care at home\n* People under legal protection, deprived of their liberty, or under legal guardianship (tutelage or curatelle) FOR THE CAREGIVER\n* Non-French speakers\n* People with cognitive or psychiatric disorders that prevent them from understanding and using the MONKA solution\n* People under legal protection, deprived of their liberty, or under legal guardianship (tutelage or curatelle)",{"count":184,"type":23},[88],"The RW-HOMECARE study is a prospective, longitudinal, real-world pilot trial designed to assess the impact of proposing the Monka digital solution to non-professional caregivers of patients discharged from emergency or short-stay units. The primary objective is to measure changes in caregiver burden using the ZBI-12 scale at baseline, 30 days, and 90 days. Secondary objectives include evaluating caregivers' physical and mental quality of life (SF-12), patient frailty (Clinical Frailty Scale), and the incidence of adverse events such as emergency visits, unplanned hospitalizations, falls, institutionalization, and death within 90 days. The study also examines the usability, acceptability, and satisfaction with Monka digital solution through standardized questionnaires, the correlation between algorithm-generated vulnerability scores and established measures, and reasons for non-adoption.\n\nEligible dyads (patient and caregiver) are recruited at discharge from emergency or short-stay units. After informed consent, caregivers receive free access to Monka digital solution for 3 months, along with a user guide. Follow-up assessments are conducted by phone at Day 30 and Day 90 (±14 days). All interventions by the coordinating nurse are tracked and analyzed quantitatively and qualitatively.",[271,272],"Frailty Syndrome","Caregiver Burden for Those Who Care for Adults With Impaired Functional Status",[274,275,276],"Frailty syndrome","Non-professional caregiver","Burden","2026-01-09",{"date":279,"type":40},"2026-01-16",{"date":281,"type":40},"2025-12-12",{"date":283,"type":23},"2027-03-12",{"name":46,"class":47},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":185,"phases":4,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":304},"100599237","study-of-the-pathophysiological-mechanisms-involved-in-the-sapho-syndrome-genetic-component-and-immune-response-100599237","NCT07081880","Study of the Pathophysiological Mechanisms Involved in the SAPHO Syndrome: Genetic Component and Immune Response","SAPHO-Screen","Inclusion Criteria:\n\n* Patient aged ≥ 18 years\n* Patient diagnosed with SAPHO syndrome\n* Weight \\> 35 kg\n* Patient affiliated with a health insurance plan\n* French-speaking patient\n* Patient who has given free, informed, and written consent\n\nExclusion Criteria:\n\n* Patient under guardianship or curatorship\n* Patient deprived of liberty\n* Patient under legal protection\n* Pregnant or breastfeeding patient",{"count":184,"type":23},"SAPHO syndrome (Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis) is a chronic inflammatory rheumatism associating bone or joint lesions and dermatological manifestations dominated by severe acne and palmar and palmoplantar pustulosis. Prevalence of SAPHO syndrome is estimated at 1\u002F50000 in France, but this figure is probably underestimated due to frequent misdiagnosis. Osteoarticular manifestations form a rheumatic picture very similar to that of other forms of spondyloarthritis (SpA). The latest French recommendations do not distinguish SAPHO syndrome from other forms of SpA. As a result, the management of SAPHO remains fairly heterogeneous, essentially based on the local experience of rheumatologists. Delays in diagnosis and difficulties in finding effective treatment can result in significant disability and reduced quality of life, particularly detrimental in a young population (age at diagnosis is usually between 30 and 40). The wide spectrum of clinical presentations of SAPHO syndrome explains the complexity of managing this condition. Understanding the pathophysiological mechanisms underlying these different forms of the disease is a major challenge for personalized medicine. SAPHO syndrome is a multifactorial disease that is a result of interaction of genetic, environmental, immunological and infectious factors. In the classification of immune-mediated inflammatory diseases, SAPHO syndrome lies midway between autoinflammatory diseases involving the innate immune response and spondyloarthritis associated with abnormalities in the adaptive immune response. Indeed, while the clinical phenotype may resemble spondyloarthritis in certain aspects, the identification of genetic forms of chronic relapsing osteitis, such as DIRA syndrome or Majeed syndrome, argues in favor of an autoinflammatory origin of SAPHO syndrome. Although osteitis is reputed to be sterile, an infectious initiating factor has long been suspected in this disease. Among the bacterial agents, antigens antigens from Cutibacterium acnes were detected in bone biopsies from patients with SAPHO syndrome. It has been suggested that this bacterium may play a role in triggering a systemic inflammatory response systemic inflammatory response mediated in particular by IL-1β.",[295],"SAPHO Syndrome","2025-12-17",{"date":298,"type":40},"2025-12-24",{"date":300,"type":40},"2025-07-15",{"date":302,"type":23},"2035-05-15",{"name":46,"class":47},2,{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":24,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":326},"100605290","benefit-on-chronic-pain-of-early-screening-and-management-of-patients-with-persistent-postoperative-pain-at-3-months-100605290","NCT07160595","Benefit on Chronic Pain of Early Screening and Management of Patients With Persistent Postoperative Pain at 3 Months","DROPS","Inclusion Criteria:\n\n* Patients who have undergone one of the following procedures:\n\n  * Inguinal hernia repair, regardless of the surgical technique used\n  * Breast reduction\n  * Mastectomy with or without reconstruction but with lymph node dissection\n  * Knee arthroscopy or knee ligamentoplasty\n\n    * Patients with a smartphone\n    * French-speaking patients\n    * Patients affiliated with a social security\n    * Patients who have given their free and informed verbal consent\n\nExclusion Criteria:\n\n* Patients with pain sensitivity defined by the presence of chronic pain, use of level 3 morphine analgesics, use of anxiolytics, gabapentinoids and\u002For antidepressants\n* Patients subject to legal protection measures\n* Patients deprived of their liberty\n* Pregnant, labouring or breastfeeding patients",{"count":313,"type":23},2052,[88],"Chronic postoperative pain has an overall incidence of approximately 30%, with 5% to 10% of cases classified as severe (numerical rating scale \\> 6\u002F10). However, its management remains suboptimal, primarily due to underdiagnosis and delayed referral of patients to specialized chronic pain centers.\n\nImproving the screening of patients with chronic postoperative pain is therefore crucial. Our research has shown that early detection of postoperative neuropathic pain is possible using just two text messages (SMS), as early as three months after surgery. Early screening, combined with prompt management, can prevent pain from becoming chronic and mitigate its harmful effects.\n\nStudy design\n\nThis study is a cluster crossover randomized trial. All participating centers (n=16) will take part in two sequential study periods:\n\n* Control Period: \"Without early treatment at 3 months\" During this period, patients with persistent postoperative pain-identified via SMS-will receive treatment at 6 months. This reflects the current standard of care for patients with postoperative pain.\n* Intervention Period: \"With early treatment at 3 months\" During this period, patients with persistent postoperative pain-identified via SMS-will receive early treatment starting at 3 months.\n\nStudy Population\n\nThe study will include patients undergoing the following minor surgical procedures:\n\n* Inguinal hernia repair\n* Breast reduction\n* Mastectomy with lymph node dissection\n* Knee arthroscopy\n* Knee ligament reconstruction\n\nStudy Schedule Recruitment Period: 24 months Patient Follow-up: 6 months Total Estimated Study Duration: 30 months",[317],"Chronic Postoperative Pain","2025-09-05",{"date":320,"type":40},"2025-09-08",{"date":322,"type":23},"2025-11",{"date":324,"type":23},"2028-04",{"name":46,"class":47},16,{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":24,"phases":335,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":48},"100601617","contribution-of-myocardial-perfusion-imaging-in-the-initial-assessment-of-acute-coronary-syndromes-without-st-elevation-for-the-diagnosis-of-myocardial-infarction-or-differential-diagnoses-100601617","NCT07112820","Contribution of Myocardial Perfusion Imaging in the Initial Assessment of Acute Coronary Syndromes Without ST Elevation for the Diagnosis of Myocardial Infarction or Differential Diagnoses","APRICOT","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Hospitalised in cardiology as an emergency for acute coronary syndrome without ST segment elevation with indication for coronary angiography within 72 hours of admission\n* Not yet undergone coronary angiography.\n* Troponin \\>99th percentile, i.e. \\>27ng\u002Fl (troponin I, hypersensitive, Abbott)\n* With de novo segmental kinetic disorder on TTE or ECG repolarisation disorder outside ST elevation\n* Patient affiliated with a health insurance scheme\n* French-speaking patient\n* Patient who has given their free, informed and written consent\n\nExclusion Criteria:\n\nHaemodynamically unstable patient: HR \\> 100 and\u002For systolic blood pressure \\\u003C 90 mmHg and\u002For diastolic blood pressure \\\u003C 60 mmHg and\u002For oxygen saturation \\\u003C 92% in AA and\u002For clinical signs of hypoperfusion (mottling, cyanosis)\n\n* Rhythmically unstable patient: sustained ventricular tachycardia, sudden death recovered.\n* Patient with a known allergy to ultrasound contrast medium\n* Patient with ST segment elevation.\n* Patient with a contraindication to MRI.\n* Patient with a caricatured picture of myocarditis (fever and\u002For significant biological inflammatory syndrome with CRP\\>50mg\u002Fl)\n* Patients already included in a type 1 interventional research protocol (RIPH1)\n* Patients under guardianship or curatorship\n* Patients deprived of their liberty\n* Patients under judicial protection\n* Pregnant or breastfeeding patients (negative pregnancy test for women of childbearing age)",{"count":184,"type":23},[88],"Patients with myocardial infarction require invasive treatment involving coronary angiography to confirm the diagnosis and, in most cases, treatment by angioplasty\u002Fstenting. Trans-thoracic ultrasound is central to the initial management of patients admitted to hospital with acute coronary syndrome without ST segment elevation.\n\nThe aim of our study is therefore to compare perfusion ultrasound with coronary angiography and MRI in this population in order to determine whether the performance is satisfactory.",[338],"Myocardial Infarction (MI)",[340,341],"acute coronary syndrome without ST segment elevation","emergency cardiology","2025-08-01",{"date":344,"type":40},"2025-08-08",{"date":346,"type":40},"2024-06-24",{"date":348,"type":23},"2026-11-30",{"name":46,"class":47},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":185,"phases":4,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":48},"100599600","typological-study-of-sleep-pathologies-during-psoriatic-rheumatism-and-sapho-syndrome-prospective-study-within-the-paris-saint-joseph-hospital-group-100599600","NCT07086599","Typological Study of Sleep Pathologies During Psoriatic Rheumatism and SAPHO Syndrome: Prospective Study Within the Paris Saint-Joseph Hospital Group\"","SleepSO2","Inclusion Criteria:\n\n* Patient aged 18 years or older\n* Patient diagnosed with psoriatic arthritis or SAPHO syndrome and followed at Paris Saint-Joseph Hospital\n* Patient presenting sleep disorders warranting hospitalization for further -investigation of these disorders\n* French-speaking patient\n* Patient who does not oppose participation in the research protocol\n\nExclusion Criteria:\n\n* Patient already followed for a sleep disorder\n* Patient who underwent polysomnography in the last 2 years\n* End-of-life patient\n* Patient under guardianship or curatorship\n* Patient deprived of liberty\n* Patient under legal protection",{"count":184,"type":23},"Chronic inflammatory rheumatisms (CIR) are a source of motor disability and various comorbidities, particularly cardiovascular and metabolic. They also significantly impact patients' quality of life, including sleep disturbances. Among CIRs, psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis, typically seronegative for rheumatoid factor. This heterogeneous disease affects peripheral and\u002For axial joints and can include extra-articular manifestations such as uveitis and chronic inflammatory bowel diseases. Its prevalence is estimated between 0.3% and 1% in the general population.\n\nSAPHO syndrome, similar to psoriatic arthritis, is characterized by specific bone involvement with a hypertrophic tendency, often affecting the axial skeleton and the anterior thoracic wall. Pain and inflammation are closely linked to sleep quality, creating a vicious cycle where pain disrupts sleep and poor sleep amplifies pain perception. Analgesic treatments, such as opioids, can also cause nocturnal respiratory pathologies, further disrupting sleep.\n\nInflammatory processes are regulated by sleep, influencing plasma concentrations of CRP, IL6, and TNF production. Patients with psoriatic arthritis or SAPHO syndrome share common risk factors with Obstructive Sleep Apnea Syndrome (OSAS), such as obesity, hypertension, and metabolic syndrome.\n\nSleep disorders are common in the general population and likely underdiagnosed in these patients. Several studies suggest a link between sleep disorders and these rheumatic conditions, affecting quality of life and exacerbating symptoms. Questionnaires like the Epworth and Pichot scales provide a more precise evaluation of these symptoms. However, objective sleep exploration through polysomnography has never been conducted in these patients.\n\nIn summary, CIRs, particularly psoriatic arthritis and SAPHO syndrome, significantly impact patients' quality of life and sleep, necessitating appropriate evaluation and management of associated sleep disorders.",[360,295,361],"Psoriasis Arthritis","Sleep Apnea Syndromes","2025-07-18",{"date":364,"type":40},"2025-07-25",{"date":366,"type":40},"2023-11-13",{"date":368,"type":23},"2027-11-01",{"name":46,"class":47},{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":18,"minAge":136,"maxAge":4,"enrollmentInfo":377,"targetDuration":379,"studyType":185,"phases":4,"briefSummary":380,"conditions":381,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":48},"100596785","para-prosthetic-valve-leak-closure-observatory---pvlc2-100596785","NCT07049991","Para-Prosthetic Valve Leak Closure Observatory - PVLC2","FFPP2","Inclusion Criteria:\n\n* ≥ 16 years and older\n* Non-opposition of the patient or child's legal representative\n* Patient referred for a percutaneous para-prosthetic leakage closure procedure\n\nExclusion Criteria:\n\n* ≤ 16 years of age\n* Refusal of the patient to participate in the observatory or the legal representative if the patient is a minor.",{"count":378,"type":23},300,"2 Years","Para-prosthetic heart valve leakage is an evolving complication after surgical or percutaneous heart valve replacement. These leaks can lead to heart failure and\u002For life-threatening hemolysis.\n\nPercutaneous closure of para-prosthetic leaks has developed as an alternative to surgery in high-risk surgical patients. These procedures remain difficult on the technical side with a significant risk of failure and complications but have been improving since the development of dedicated prostheses and the increase in operator experience.\n\nA sharing of experience through the creation of an international expert group has been initiated since 2017 formalised by biannual expert meetings, the elaboration of recommendations in progress and the establishment of an international observatory PVLC1(CCTIRS N°16-62) on 2017-2019.\n\nBeyond the technical aspects and the follow-up of major cardiovascular events collected in PVLC1, the investigators also wonder what impact these procedures have on the quality of life of patients. The investigators suggest that even a partial decrease in para-prosthetic leakage may be associated with an improvement in quality of life by reducing the need for transfusion and\u002For reducing dyspnea.\n\nA new PVLC2 study is justified to continue the evolutionary follow-up of the technical and clinical results of these procedures, accompanied by the evaluation of the possible benefit on the quality of life of the patients.",[382],"Para-prosthetic Heart","2025-06-25",{"date":385,"type":40},"2025-07-03",{"date":387,"type":40},"2020-01-01",{"date":389,"type":23},"2027-07-01",{"name":46,"class":47},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":185,"phases":4,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":48},"100578423","determinants-of-decisional-autonomy-in-chronic-pain-patients-and-assessment-of-treatment-effectiveness-100578423","NCT06811103","DEterminants of Decisional Autonomy In Chronic Pain Patients and Assessment of Treatment Effectiveness","DEDICATE","Inclusion Criteria:\n\n* Patient aged 18 years or older\n* Patient attending their first consultation for chronic pain between 01\u002F01\u002F2025 and 31\u002F12\u002F2025\n* Francophone patient\n* Patient capable of expressing their non-opposition to participation\n\nExclusion Criteria:\n\n* Patient with significant visual or hearing impairment\n* Patient under guardianship or curatorship\n* Patient deprived of liberty\n* Patient under judicial protection Patient who opposes the use of their data for this research",{"count":86,"type":23},"Chronic pain is defined as an unpleasant sensory and emotional experience that persists for three months or more, affecting 20-30% of the global adult population. It can arise from primary conditions or as a consequence of diseases and is a significant source of disability. Chronic pain is no longer merely a symptom but often a disease itself, with neurological and psychosocial mechanisms. The biopsychosocial model introduced by George Engel in 1977 helps to consider the biological, psychological, social, and societal dimensions of chronic pain. Patients with chronic pain must adapt to new circumstances, acquiring new knowledge and coping skills to reach a new homeostasis. The goal is not necessarily pain elimination but enabling patients to manage their pain and continue daily activities effectively.\n\nInternational guidelines suggest a patient-centered, interdisciplinary approach to managing chronic pain, with an emphasis on empowering patients, motivating them, and involving them in decision-making. Autonomy in decision-making is crucial in this context, encompassing both negative freedom (absence of external constraints) and positive freedom (the ability to make choices and realize one's potential). However, chronic pain can limit cognitive and functional abilities, potentially impeding a patient's autonomy. Research indicates that a significant proportion of chronic pain patients experience a deficit in decision-making autonomy.\n\nThis mixed-methods study aims to explore the determinants of decision-making autonomy in chronic pain patients and its impact on their treatment. Using the MacCAT-T assessment tool, which evaluates understanding, reasoning, appreciation, and choice expression, the study will examine the relationship between patients' autonomy levels and their health outcomes. The study will also assess how clinicians perceive patients' autonomy compared to the tool's findings.",[401],"Chronic Pain","2025-06-18",{"date":404,"type":40},"2025-06-24",{"date":406,"type":40},"2025-03-01",{"date":408,"type":23},"2027-10-30",{"name":46,"class":47},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":24,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":428},"100520833","identification-of-individual-histological-and-blood-markers-in-patients-with-recurrent-or-metastatic-upper-aerodigestive-tract-squamous-cell-carcinoma-in-response-to-immunotherapies-100520833","NCT06061705","Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies","iMonitORL","Inclusion Criteria:\n\n* Patients aged ≥ 18 years\n* Patients with histologically confirmed CEVADS involving the oral cavity, oropharynx, hypopharynx or larynx\n* Pre-treated patients with a first recurrence (locoregional or metastatic) who are candidates for immunotherapy\n* Patient affiliated to a health insurance plan\n* French-speaking patient\n* Patient with free, informed and written consent\n\nExclusion Criteria:\n\n* Patients with a contraindication to immunotherapy (transplant patients)\n* Pregnant or breast-feeding patients\n* Patient under guardianship or curatorship\n* Patient under court protection\n* Patient deprived of liberty",{"count":184,"type":23},[88],"Epidermoid Carcinoma of the Upper Aerodigestive Tract (CEVADS) is the 6th most common cancer worldwide. Despite current therapies (radiotherapy, surgery and chemotherapy), cancers of the Upper Aerodigestive Tract (UAT) have a poor prognosis, with a 10-year survival rate of no more than 20%.\n\nFor recurrent or metastatic CEVADS, the therapeutic arsenal, based for many years on chemotherapy and anti-EGFR (Epidermal Growth Factor Receptor) agents, has been enriched by a new therapeutic class: PD-1 inhibitors. For CEVADS, PD-1 inhibitors have been approved for second-line treatment of nivolumab for over a year, and are now used in first-line treatment of pembrolizumab.\n\nThe results of this therapeutic class in CEVADS are not as spectacular as for melanoma or bronchial cancer. Indeed, only 20% of patients have a favorable response, compared with half who experience disease progression. This low proportion of responders can be explained by tumor heterogeneity within CEVADS and poor patient selection.\n\nThe only marker used to select patients is PD-L1 expression detected by ImmunoHistochemistry (IHC). However, it seems that this marker, described as imperfect, is still little explored in ENT. It needs to be compared with the expression of other cell lines in the tumor microenvironment, which could play an important role in resistance to PD-1 inhibitors.\n\nIHC identifies all macrophages using the CD68 marker, while the CD163 marker is specific to M2 macrophages.\n\nOther targets in the microenvironment are also being investigated, with the discovery of a Tertiary Lymphocyte Structure (TLS) in melanoma treated with immunotherapy.\n\nIt therefore seems necessary to gain a better understanding of the mechanisms of tumor progression under immunotherapy in order to develop strategies to optimize response to treatment. This would enable better selection of patients likely to benefit from immunotherapy, and open up prospects for therapeutic combinations.\n\nThe hypothesis is that macrophages, but also other cells and factors in the CEVADS microenvironment, play a decisive role in resistance to PD-1 inhibitors. The aim is therefore to continue these macrophage analyses, extend them to other cells in the microenvironment and link them to other prognostic factors under investigation.\n\nA prospective study will analyze tumor tissue during treatment with PD-1 inhibitors, in order to correlate all the factors studied with response or resistance to immunotherapies.\n\nIn addition, the oral microbiota, in the lineage of the intestinal microbiota, has been shown to be highly stable over time and to play a role in the oncogenesis of certain cancers, notably CEVADS. Like the intestinal microbiota, it could also represent a prognostic factor in the response to immunotherapies.\n\nOf all the bacteria in this oral microbiota, one has been shown to play a major role: Fusobacterium nucleatum (F. nucleatum). However, little is known about the mechanism of action of intratumoral F. nucleatum on the development of CEVADS. In particular, it is thought to play a role in local cancer immunity, via macrophages, regulatory T cells (Tregs) and TLRs. Finally, it appears that specific antimicrobial T-cell responses may cross-react with tumor antigens, hence the importance of also analyzing the metabolome of commensal bacteria.The aim of this study was to evaluate the evolution of the presence of this bacterium in saliva, as well as the specific immune response to F. nucleatum in patients with CEVADS during immunotherapy treatment.",[421],"Squamous Cell Carcinoma of the Oropharynx",{"date":404,"type":40},{"date":424,"type":40},"2024-01-29",{"date":426,"type":23},"2026-06-30",{"name":46,"class":47},3,{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":18,"minAge":436,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":185,"phases":4,"briefSummary":439,"conditions":440,"keywords":442,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":455,"leadSponsor":457,"locationsCount":458},"100579387","an-international-multicenter-study-on-transcatheter-device-closure-of-perimembranous-ventricular-septal-defects-100579387","NCT06823635","An International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects","PERI-CLOSE","Inclusion Criteria:\n\n1. Patients with perimembranous ventricular septal defects (PmVSD), as defined by 2D transthoracic echocardiography according to previously published classifications.\n2. Defect size between 3 mm and \\\u003C20 mm on the left ventricular side, as measured by 2D echocardiography.\n3. Left-to-right ventricular shunt.\n4. Age ≥3 months and body weight≥5 kg.\n5. Symptomatic patients (heart failure, failure to thrive, recurrent respiratory infections, and rest or exercise dyspnea) or asymptomatic patients with progressive heart enlargement.\n6. History of infective endocarditis related to the PmVSD or hemodynamically significant PmVSD with: Qp\u002FQs \\>1.5 on catheterization, left ventricular volume overload (LVEDD z-score \\>2) based on echocardiography, or pulmonary hypertension on catheterization (mean pulmonary artery pressure \\>20 mmHg).\n7. Presence or absence of aortic valve prolapse, with or without regurgitation.\n8. Presence or absence of a membranous septal aneurysm, with or without inlet or outlet extension.\n\nExclusion Criteria:\n\n1. Eisenmenger physiology (pulmonary vascular resistance \\> 8 Wood units, nonreactive) with an exclusive right-to-left shunt.\n2. Pre-existing complete heart block or high-risk proximity of the conduction system to the defect without prior pacemaker implantation.\n3. Severe aortic or tricuspid valve disease requiring surgical or catheter-based intervention.\n4. Pregnancy or planned pregnancy if the procedure involves X-ray exposure.\n5. Extensive congenital cardiac anomalies requiring surgery.\n6. Thrombus at the implant site or documented venous thrombus in access vessels.\n7. Sepsis, active endocarditis, or bacterial infections within one month pre-procedure.\n8. Uncontrolled bleeding or clotting disorders.\n9. Contraindications to antiplatelet therapy or refusal of blood transfusions.\n10. Cardiac malformations dependent on the presence of a perimembranous ventricular septal defect (PmVSD).\n11. Lack of informed written consent for the procedure\n12. Failure to attend any follow-up visit post-discharge.\n13. Patients under guardianship or curatorship\n14. Patients deprived of liberty\n15. Patients under court protection\n16. Patients or legal guardians refusing the use of personal data for this research","3 Months",{"count":438,"type":23},1000,"The international multicenter registry aims to gather real-world data on patient outcomes and assess the procedural success and performance of various device occluders used in the transcatheter treatment of pediatric and adult patients with perimembranous ventricular septal defects (PmVSD).",[441],"Perimembranous Ventricular Septal Defect",[443,444,445,446,447,448,449,450],"Cardiovascular Abnormalities","Congenital Heart Disease","Device Closure","Heart Defects, Congenital","Heart Septal Defects","Heart Septal Defects, Ventricular","Transcatheter Interventions","Ventricular Septal Defects","2025-02-07",{"date":453,"type":40},"2025-02-12",{"date":406,"type":23},{"date":456,"type":23},"2026-07-31",{"name":46,"class":47},18,{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":185,"phases":4,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":48},"100578421","evaluation-of-individual-health-coaching-sessions-provided-by-a-patient-expert-as-part-of-therapeutic-education-for-patients-registered-at-the-chronic-pain-consultation-100578421","NCT06811077","Evaluation of Individual Health Coaching Sessions Provided by a Patient Expert As Part of Therapeutic Education for Patients Registered At the Chronic Pain Consultation","As Part of Therapeutic Education for Patients Registered At the Chronic Pain Consultation","COADOL","Inclusion Criteria:\n\n* Patient aged ≥ 18 years\n* Patients followed in chronic pain consultations referred to the therapeutic education workshops\n* Patient affiliated with a health insurance plan\n* French-speaking patient\n* Patient capable of giving oral, informed, and explicit consent\n\nExclusion Criteria:\n\n* Patient with psychiatric disorders making inclusion in group workshops impossible\n* Patient unwilling to participate in individual coaching sessions Patient under guardianship or curatorship Patient deprived of liberty Patient under legal protection Pregnant or breastfeeding patient",{"count":468,"type":23},30,"Chronic pain is defined as a persistent sensory and emotional experience, lasting for more than three months, and often resistant to treatment. It can result from various conditions, including life-threatening diseases, accidents, or therapeutic procedures like surgery or chemotherapy. Chronic pain significantly impacts a patient's physical and psychological well-being, often leading to body image issues and functional deterioration in daily activities, both at home and at work or school. The World Health Organization recognized chronic pain as a disease in 2019. Chronic pain patients must adapt to their condition, acquiring new skills and knowledge through therapeutic education. Group sessions, a key part of therapeutic education, help break the isolation felt by many patients, fostering shared experiences and mutual support. Since 2015, the Saint-Joseph Hospital's chronic pain consultation has offered group education workshops, inspired by those at the Pitié-Salpêtrière hospital in Paris. However, many patients struggle to apply new skills independently after these workshops. In response, individualized coaching was introduced in 2020. This approach, led by a health coach who is also an expert patient, provides personalized support to help patients set and achieve realistic goals, fostering active engagement in their lives through tailored strategies and ongoing support.\n\nThe main aim of this pilot study is to assess the quantitative and qualitative contribution of personalized support by an \"expert patient\" chronic pain coach (individual coaching), on the functional and emotional impact and emotional impact of their pain, in patients followed up in a chronic pain consultation and having group therapeutic education workshops.",[401],"2025-02-05",{"date":473,"type":40},"2025-02-10",{"date":475,"type":40},"2025-02-03",{"date":477,"type":23},"2027-01-15",{"name":46,"class":47},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":185,"phases":4,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":494,"leadSponsor":496,"locationsCount":48},"100578599","prevalence-of-central-neuropathic-pain-after-a-stroke-in-patients-attending-post-stroke-consultations-in-the-le-de-france-region-100578599","NCT06813391","Prevalence of Central Neuropathic Pain After a Stroke in Patients Attending Post-stroke Consultations in the Île-de-France Region","AVCD","Inclusion Criteria:\n\n* Patient aged ≥18 years\n* Patient attending a post-stroke consultation (3 to 6 months after the stroke)\n* Stroke confirmed by imaging (MRI or CT scan)\n* Francophone patient\n* Patient not opposing participation in the study\n\nExclusion Criteria:\n\n* Patient with cognitive or communication disorders preventing them from completing the questionnaires (as assessed by the investigator)\n* Patient under guardianship or curatorship\n* Patient deprived of liberty\n* Patient under judicial protection",{"count":487,"type":23},500,"Post-stroke pain is common, affecting 15-50% of patients and significantly impacting their quality of life, rehabilitation, and functional recovery. There are different types of post-stroke pain, including peripheral pain related to spasticity, shoulder pain, complex regional pain syndrome, and headaches, as well as central pain linked to brain lesions. Central Post-Stroke Pain (CPSP) is diagnosed when the pain has neuropathic characteristics (burning, cold, tightness, compression), possibly accompanied by allodynia, hyperesthesia, and sensory-motor disorders localized to the area affected by the stroke. CPSP disrupts sleep, impairs functional rehabilitation, and can lead to depression, anxiety, substance abuse, and cognitive disorders. The prevalence of CPSP varies, ranging from 1% to 35%, but it is likely underreported due to difficulties in detection caused by cognitive or communication issues, the clinical variability of CPSP, and its coexistence with other types of post-stroke pain.\n\nCPSP often remains resistant to standard neuropathic pain treatments, such as anticonvulsants and antidepressants, which may cause side effects that reduce patients' autonomy and quality of life. Non-pharmacological therapies used in other chronic pain conditions may offer promising alternatives, but have not been widely studied in CPSP. Improved clinical characterization of CPSP patients is essential. Following a 2015 decree by the French Ministry of Health, post-stroke consultations are standardized, providing a good opportunity for systematic pain screening. The study proposes a systematic screening of different types of pain during post-stroke consultations, categorizing patients into three groups: those with CPSP, those with pain from another mechanism, and those without pain.",[490,491],"Stroke Sequelae","Neuropathic Pain",{"date":451,"type":40},{"date":406,"type":23},{"date":495,"type":23},"2026-10-01",{"name":46,"class":47},{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":24,"phases":506,"briefSummary":507,"conditions":508,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":513,"leadSponsor":515,"locationsCount":48},"100578446","combinaison-of-virtual-reality-and-rehabilitation-to-improve-muscle-function-exercise-tolerance-exertional-symptoms-and-dyspnea-in-patients-with-chronic-respiratory-disease-a-randomized-cross-over-trial-100578446","NCT06811402","Combinaison of Virtual Reality and Rehabilitation to Improve Muscle Function, Exercise Tolerance, Exertional Symptoms and Dyspnea in Patients with Chronic Respiratory Disease: a Randomized Cross-over Trial","OVERMUSCLED","Inclusion Criteria:\n\n* Patient aged 18 years or older\n* Patient with a chronic respiratory disease requiring pulmonary rehabilitation\n* Patient with dyspnea assessed as mMRC ≥ 0 (Annex 3)\n* Patient undergoing pulmonary rehabilitation at the Paris Saint-Joseph Hospital\n* Patient affiliated with a health insurance plan\n* French-speaking patient\n* Patient who has provided informed, explicit, and voluntary oral consent\n\nExclusion Criteria:\n\n* Contraindications for an endurance reconditioning program (neurodegenerative diseases, severe neurological deficits, unstable cardiovascular diseases)\n* History of motion sickness, vertigo, vestibular impairment, labyrinthitis\n* History of seizures or other neurological or psychiatric comorbidities\n* Severe visual impairments\n* Patient already included in a Type 1 interventional research protocol (RIPH1)\n* Patient under guardianship or curatorship\n* Patient deprived of liberty\n* Patient under legal protection\n* Pregnant or breastfeeding patient",{"count":505,"type":23},26,[88],"Chronic respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD), are a leading cause of death globally. These diseases not only contribute significantly to mortality but also lead to a decline in physical capacity, limiting daily activities and perpetuating a vicious cycle of deconditioning. Dyspnea (shortness of breath) is a major symptom, seen in 56 to 98% of COPD patients, and is linked to decreased exercise tolerance and muscle dysfunction. It often leads to reduced physical activity, further worsening respiratory function and quality of life. Dyspnea severity is associated with increased mortality, hospitalizations, and anxiety. The main therapeutic approach for these patients is pulmonary rehabilitation, which improves exercise tolerance, quality of life, and reduces hospitalizations and exacerbations. However, dyspnea limits exercise and is often a barrier to continued physical activity.\n\nVirtual reality (VR) technology has shown promise in managing symptoms like pain, anxiety, and dyspnea by providing a distraction. Studies suggest that VR can improve dyspnea and anxiety, particularly in patients hospitalized for conditions like COVID-19. However, research on VR's immediate effects on exercise capacity is limited, with most studies focusing on non-immersive exergames rather than immersive VR. The potential of VR to improve exercise tolerance in patients with chronic respiratory diseases remains uncertain. Our study aims to test this hypothesis through a randomized crossover trial to assess VR's impact on dyspnea and exercise tolerance in these patients.",[509],"Chronic Obstructive Pulmonary Disease",{"date":511,"type":40},"2025-02-06",{"date":406,"type":23},{"date":514,"type":23},"2025-12-31",{"name":46,"class":47},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":24,"phases":526,"briefSummary":527,"conditions":528,"keywords":532,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":546},"100568995","postoperative-extubation-in-hypoxemic-patients-100568995","NCT06688487","Postoperative Extubation in Hypoxemic Patients","Early Postoperative Extubation in Hypoxemic ICU Patients: a Multicenter, Randomized Controlled Trial","EPHYRE","Inclusion Criteria:\n\n* Francophone patient affiliated to a health insurance plan;\n* Patient having granted free, informed and written consent to participate in the study;\n* Patient with hypoxemia defined as SpO2 ≤ 90% under 6 L\u002Fmin or FiO2 40% during spontaneous breathing trial.\n\nExclusion Criteria:\n\n* Presence of hypercapnia at the end of SBT (PaCO2 above 50 mmHg);\n* Presence of severe hypoxemia during SBT defined by SpO2 below 86% under 9 L\u002Fmin or FiO2 = 50%;\n* Presence of poor clinical tolerance of SBT defined by polypnoea above 30\u002Fmin, agitation, sweating, hypertension (PAS above 180 mmHg), tachycardia (HR above 140 bpm) or arrhythmia;\n* Presence of an ineffective cough or major bronchial congestion;\n* Patient already included in a type 1 interventional research protocol (RIPH1), modifying the procedure for ventilatory weaning and\u002For ventilatory support after extubation;\n* Anatomical factors precluding the use of NIV or high-flow oxygen therapy, notably facial or cervico-facial malformations;\n* Tracheostomized patient;\n* History of obstructive ventilatory disorders with indication for NIV post-extubation, chronic obstructive pulmonary disease (COPD) GOLD score III\u002FIV;\n* History of obstructive sleep apnea syndrome with equipment;\n* cardiogenic pulmonary edema;\n* Patient on extracorporeal membrane oxygenation (ECMO) at the time of inclusion;\n* Patient under guardianship or curatorship;\n* Minor patients;\n* Patient deprived of liberty or under court protection;\n* Pregnant or breast-feeding women;\n* Patient in therapeutic limitation with decision not to re-intubate.",{"count":525,"type":23},152,[88],"The objective of this clinical trial is to assess whether early extubation of patients with hypoxemia during the spontaneous breathing trial (SBT) shortens the duration of ventilatory support. The trial will also evaluate the safety of this approach. The key research questions include:\n\nDoes early extubation of hypoxemic patients reduce the total duration of ventilatory support (both invasive and non-invasive) by 36 hours? Does early extubation of hypoxemic patients increase the number of ventilator-free days by day 28? Can the safety of early extubation in hypoxemic patients be ensured by confirming no significant differences in rates of reintubation, tracheostomy, or mortality? The trial will compare ventilatory outcomes between two groups: hypoxemic patients who undergo early extubation (hypoxemic extubation group) and those who remain on invasive ventilation until hypoxemia resolves (conventional extubation group).",[529,530,531],"Hypoxemia","Extubation","Postoperative Respiratory Complication",[533,534,535,536,537],"extubation","hypoxemia","postoperative respiratory complication","weaning","facilitative non invasive strategy","2024-11-12",{"date":540,"type":40},"2024-11-14",{"date":542,"type":23},"2024-11-18",{"date":544,"type":23},"2027-01-31",{"name":46,"class":47},12,{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":224,"minAge":19,"maxAge":555,"enrollmentInfo":556,"targetDuration":4,"studyType":24,"phases":557,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":304},"100566812","influence-of-bodily-practices-on-the-quality-of-life-of-women-with-endometriosis-100566812","NCT06660043","Influence of Bodily Practices on the Quality of Life of Women With Endometriosis","Influence of Bodily Practices on the Quality of Life of Women","PCKendo","Inclusion Criteria:\n\n* Menstruating women aged 18 to 55;\n* proven diagnosis of endometriosis (pelvic ultrasound or MRI)\n* Having endometriosis-related pain of a level higher than 3 on the VAS scale and\u002For chronic incapacitating symptoms related to endometriosis;\n* Patient without treatment or with stable endometriosis treatment (pill and\u002For ATG) who has not undergone treatment during the last 6 months;\n* Patient affiliated to a health insurance scheme;\n* French-speaking patient;\n* Patient having given free, informed and express oral consent.\n\nExclusion Criteria:\n\n* Any patient whose endometriosis treatment has been modified for less than 6 months;\n* Having endometriosis-related pain greater than or equal to 8 on the VAS scale;\n* Cardiovascular risks related to physical training;\n* Inability to perform proposed exercises;\n* Patient under guardianship;\n* Patient deprived of liberty;","55 Years",{"count":58,"type":23},[88],"This research focuses on understanding how physical activity can improve the quality of life for women with endometriosis by enhancing their self-perception, particularly regarding their physical abilities and appearance. The study is based on the idea that improving internal perceptions can lead to better overall well-being for these women. Previous studies, suggest that physical self-perception plays a crucial role in shaping an individual's quality of life. There is also evidence supporting a reciprocal relationship between physical self-concept and participation in physical activity\n\nIn this context, the research aims to explore how physical activity could positively influence the self-concept of women suffering from endometriosis, which in turn could enhance their quality of life. By focusing on improving both physical abilities and body image through regular exercise, this study seeks to offer insights into potential therapeutic approaches for managing the physical and psychological impacts of endometriosis.",[560],"Endometriosis","2024-10-24",{"date":563,"type":40},"2024-10-26",{"date":565,"type":40},"2024-03-21",{"date":567,"type":23},"2025-03-20",{"name":46,"class":47},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":24,"phases":579,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":48},"100548774","impact-of-performing-a-rapid-antibiotic-susceptibility-test-on-antibiotic-therapy-adaptation-in-adult-patients-with-enterobacterales-bacteremia-100548774","NCT06425367","Impact of Performing a Rapid Antibiotic Susceptibility Test on Antibiotic Therapy Adaptation in Adult Patients with Enterobacterales Bacteremia","Impact of Performing a Rapid Antibiotic Susceptibility Test (MHR-SIR) on Antibiotic Therapy Adaptation in Adult Patients with Enterobacterales Bacteremia, Controlled, Randomized Cluster and Cross-over Study","MHR-Blood","Inclusion Criteria:\n\n* age \\>= 18\n* Patient hospitalized in a clinical department of each participating center\n* Patient managed in the context of bacteremia (microbiological criterion = positive blood culture)\n* Patient with positive blood culture for Enterobacterales\n* Patient affiliated to a health insurance scheme\n* Patient\u002Frelative having given free, informed and express oral consent\n\nExclusion Criteria:\n\n* Patients with non-enterobacterial bacteremia\n* Patient under guardianship\n* Patient deprived of liberty\n* Patient under court protection\n* Pregnant or breast-feeding patient",{"count":578,"type":23},960,[88],"Bacteremia is defined as the presence of bacteria in the blood. They can potentially lead to life-threatening septic shock.\n\nEffective probabilistic antibiotic therapy must therefore be initiated immediately after blood cultures have been taken.\n\nTo diagnose bacteremia, blood culture bottles must first be incubated, which allows bacterial growth and early detection. Then, as soon as the sample is positive, an antibiogram of the incriminated bacterium is carried out by inoculation on MH (Mueller Hinton) medium. This diffusion antibiogram is the reference method and is obtained 24 hours after the vial is positive, i.e. around 48 hours after blood cultures are taken.\n\nAmerican recommendations agree that it is crucial to use rapid diagnostic tests to obtain the antibiogram. Antibiotic susceptibility test data can be used to broaden the spectrum of antibiotics in the event of ineffective therapy. They can also be used to reduce the spectrum of broad-spectrum antibiotics. This is part of the proper use of antibiotics and the reduction of multi-resistant bacteria (MRB) or highly resistant bacteria (HRB). Finally, it is also possible to carry out an early oral relay, thus avoiding intravenous infusions and their complications, and potentially reducing hospitalization times.\n\nThe investigators have evaluated a rapid antibiogram by diffusion on MHR-SIR (Mueller-Hinton Rapid-SIR) medium from the blood culture bottle. The investigators were able to obtain antibiogram results 7 hours after blood culture positivity, with excellent correlation compared with the standard method after 24 hours incubation on MH (Mueller-Hinton). The antibiotics tested were the same as with the standard method.\n\nSecondly, The investigators were able to evaluate prospectively the impact of diffusion antibiotic susceptibility testing on MHR-SIR medium on early modification of antibiotic therapy in bacteremia, on 167 patients Antibiotic susceptibility test data on MHR-SIR enabled us to adapt antibiotic therapy 8 hours after blood culture positivity for 74 patients (44%). Antibiotic therapy was ineffective for 30 patients (18%) and was therefore extended. It also enabled us to reduce the spectrum of antibiotic therapy, in particular through early oral relay, for 44 patients (26%).\n\nThe aim of this multicenter trial is to validate on a large scale this strategy for obtaining rapid antibiotic susceptibility test results, with significant consequences in terms of optimizing antibiotic therapy.",[582],"Bacteremia",[584,585],"antibiogram","bacteremia","2024-09-25",{"date":588,"type":40},"2024-09-27",{"date":590,"type":40},"2024-08-12",{"date":592,"type":23},"2025-08-15",{"name":46,"class":47},""]